Small-molecule inducer of cancer cell polyploidy promotes apoptosis or senescence: Implications for therapy

Cell Cycle

Volumn 9, Issue 16, 2010, Pages 3384-3395

  Tovar, Christian ^a   Higgins, Brian ^a   Deo, Dayanand ^a   Kolinsky, Kenneth ^a   Liu, Jin Jun ^a   Heimbrook, David C ^a   Vassilev, Lyubomir T ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

Apoptosis; Mitotic checkpoint; Polyploidy; Senescence; Tubulin

Indexed keywords

ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUB3 PROTEIN; DNA; NOCODAZOLE; R1530; TUBULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER THERAPY; CELL CYCLE ARREST; CELL LINE; CELL PROLIFERATION; CELL STRAIN HCT116; CHROMOSOME NUMBER; CONTROLLED STUDY; DNA REPLICATION; DOWN REGULATION; DRUG EFFICACY; ENDOREDUPLICATION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MITOSIS; MITOSIS INHIBITION; MITOSIS SPINDLE; MOUSE; NONHUMAN; POLYPLOIDY; PROTEIN POLYMERIZATION; SENESCENCE; TUMOR XENOGRAFT;

EID: 77955721945     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.16.12732     Document Type: Article

References (35)

1. Ganem NJ, Storchova Z, Pellman D. Tetraploidy, aneuploidy and cancer. Curr Opin Genet Dev 2007; 17:157-62.
2. Storchova Z, Kuffer C. The consequences of tetraploidy and aneuploidy. J Cell Sci 2008; 121:3859-66.
3. Ricke RM, van Ree JH, van Deursen JM. Whole chromosome instability and cancer: A complex relationship. Trends Genet 2008; 24:457-66.
4. Storchova Z, Pellman D. From polyploidy to aneuploidy, genome instability and cancer. Nat Rev Mol Cell Biol 2004; 5:45-54.
5. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004; 23:2825-37.
6. Ganem NJ, Pellman D. Limiting the proliferation of polyploid cells. Cell 2007; 131:437-40.
7. Vassilev LT, Tovar C, Chen S, Knezevic D, Zhao X, Sun H, et al. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc Natl Acad Sci USA 2006; 103:10660-5.
8. 2/M phase border by reversible inhibition of CDK1. Cell Cycle 2006; 5:2555-6.
9. Thompson T, Tovar C, Yang H, Carvajal D, Vu BT, Xu Q, et al. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J Biol Chem 2004; 279:53015-22.
10. Demidenko ZN, Blagosklonny MV. Quantifying pharmacologic suppression of cellular senescence: Prevention of cellular hypertrophy versus preservation of proliferative potential. Aging (Albany NY) 2009; 1:1008-16.
11. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995; 92:9363-7.
12. Huang B, Deo D, Xia M, Vassilev LT. Pharmacologic p53 Activation Blocks Cell Cycle Progression but Fails to Induce Senescence in Epithelial Cancer Cells. Mol Cancer Res 2009; 7:1497-509.
13. Roninson IB. Tumor cell senescence in cancer treatment. Cancer Res 2003; 63:2705-15.
14. Goldstein DM, Gray NS, Zarrinkar PP. High-throughput kinase profiling as a platform for drug discovery. Nat Rev Drug Discov 2008; 7:391-7.
15. Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, et al. Inhibition of drug-resistant mutants of ABL KIT and EGF receptor kinases. Proc Natl Acad Sci USA 2005; 102:11011-6.
16. Li JJ, Li SA. Mitotic kinases: The key to duplication, segregation and cytokinesis errors, chromosomal instability and oncogenesis. Pharmacol Ther 2006; 111:974-84.
17. Habedanck R, Stierhof YD, Wilkinson CJ, Nigg EA. The Polo kinase Plk4 functions in centriole duplication. Nat Cell Biol 2005; 7:1140-6.
18. Johnson EF, Stewart KD, Woods KW, Giranda VL, Luo Y. Pharmacological and functional comparison of the polo-like kinase family: Insight into inhibitor and substrate specificity. Biochemistry 2007; 46:9551-63.
19. Vader G, Lens SM. The Aurora kinase family in cell division and cancer. Biochim Biophys Acta 2008; 1786:60-72.
20. Barr AR, Gergely F. Aurora-A: The maker and breaker of spindle poles. J Cell Sci 2007; 120:2987-96.
21. Ko MA, Rosario CO, Hudson JW, Kulkarni S, Pollett A, Dennis JW, et al. Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis. Nat Genet 2005; 37:883-8.
22. Hau PM, Siu WY, Wong N, Lai PB, Poon RY. Polyploidization increases the sensitivity to DNA-damaging agents in mammalian cells. FEBS Lett 2006; 580:4727-36.
23. Margolis RL. Tetraploidy and tumor development. Cancer Cell 2005; 8:353-4.
24. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005; 24:2899-908.
25. Yen TJ, Kao GD. Mitotic checkpoint, aneuploidy and cancer. Adv Exp Med Biol 2005; 570:477-99.
26. Suijkerbuijk SJ, Kops GJ. Preventing aneuploidy: The contribution of mitotic checkpoint proteins. Biochim Biophys Acta 2008; 1786:24-31.
27. May KM, Hardwick KG. The spindle checkpoint. J Cell Sci 2006; 119:4139-42.
28. Malumbres M, Barbacid M. Cell cycle kinases in cancer. Curr Opin Genet Dev 2007; 17:60-5.
29. Kleylein-Sohn J, Westendorf J, Le Clech M, Habedanck R, Stierhof YD, Nigg EA. Plk4-induced centriole biogenesis in human cells. Dev Cell 2007; 13:190-202.
30. 1 tetraploidy checkpoint and the suppression of tumorigenesis. J Cell Biochem 2003; 88:673-83.
31. Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res 2005; 65:1918-24.
32. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 2006; 103:1888-93.
33. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303:844-8.
34. Xia M, Knezevic D, Tovar C, Huang B, Heimbrook DC, Vassilev LT. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation. Cell Cycle 2008; 7:1604-12.
35. Huang B, Vassilev LT. Reduced transcriptional activity in the p53 pathway of senescent cells revealed by the MDM2 antagonist nutlin-3. Aging (Albany NY) 2009; 1:845-54.